ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells

Salma Kaochar,1,2 Jianrong Dong,2 Marie Torres,3 Kimal Rajapakshe,2 Fotis Nikolos,2 Christel M. Davis,5 Erik A. Ehli,5 Cristian Coarfa,2,6 Nicholas Mitsuaides,1,2,6 and Vasiliki Poulaki3,4

1Department of Medicine, Baylor College of Medicine, Houston, Texas, United States
2Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States
3Department of Ophthalmology, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, United States
4Boston University School of Medicine, Boston, Massachusetts, United States
5Avera Institute for Human Genetics, Sioux Falls, South Dakota, United States
6Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, United States

Correspondence: Vasiliki Poulaki, Department of Ophthalmology, Veterans Affairs Boston Healthcare System, Boston University School of Medicine, Boston, MA 02130, USA; poulakiv@gmail.com.
Submitted: June 18, 2017
Accepted: October 2, 2017

PURPOSE. Uveal melanoma (UM) is uniformly refractory to all available systemic chemotherapies, thus creating an urgent need for novel therapeutics. In this study, we investigated the sensitivity of UM cells to ICG-001, a small molecule reported to suppress the Wnt/β-catenin-mediated transcriptional program.

METHODS. We used a panel of UM cell lines to examine the effects of ICG-001 on cellular proliferation, migration, and gene expression. In vivo efficacy of ICG-001 was evaluated in a UM xenograft model.

RESULTS. ICG-001 exerted strong antiproliferative activity against UM cells, leading to cell cycle arrest, apoptosis, and inhibition of migration. Global gene expression profiling revealed strong suppression of genes associated with cell cycle proliferation, DNA replication, and G1/S transition. Gene set enrichment analysis revealed that ICG-001 suppressed Wnt, mTOR, and MAPK signaling. Strikingly, ICG-001 suppressed the expression of genes associated with UM aggressiveness, including CDH1, CITED1, EMP1, EMP3, SDCBP, and SPARC. Notably, the transcriptomic footprint of ICG-001, when applied to a UM patient dataset, was associated with better clinical outcome. Lastly, ICG-001 exerted anticancer activity against a UM tumor xenograft in mice.

CONCLUSIONS. Using in vitro and in vivo experiments, we demonstrate that ICG-001 has strong anticancer activity against UM cells and suppresses transcriptional programs critical for the cancer cell. Our results suggest that ICG-001 holds promise and should be examined further as a novel therapeutic agent for UM.

Keywords: uveal melanoma (UM), ICG-001, Wnt signaling, metastasis

Uveal melanoma (UM), the most common intraocular malignancy in adults, arises from melanin-producing melanocytes of the iris, ciliary body, or choroid. Primary UM can be treated effectively via irradiation (radiotherapy with charged particles or radioactive iodine). Unfortunately, approximately 50% of UM patients suffer metastatic disease; among those, more than 90% have involvement of the liver, with the lung (24%), bones (16%), and skin (11%) also being common metastatic sites.2–6 Metastatic UM is uniformly refractory to all available systemic chemotherapies,7,8 creating an unmet need for novel, effective, targeted therapies.

In recent years, intense efforts have been made to increase our understanding of the molecular pathophysiology of UM. Sequencing studies have shown that approximately 85% of UMs harbor an activating somatic mutation in the G-protein α subunits, Gαq or Gz11,9,10 leading to constitutive activation of the protein kinase C (PKC) and the MEK signaling pathways. Cytogenetic profiling identified frequent large-scale aberrations in chromosomes 1, 5, 6, and 8,11–15 as well as small scale changes, such as deletions (e.g., loss of the tumor suppressor gene PTEN located on chromosome 10q), and amplifications (e.g., gain of proto-oncogenes, such as MYC (43%) and BCL2 (95%).16 Moreover, gene expression profiling studies have identified at least two distinct classes of gene sets: Class 1, associated with low risk of metastasis and Class 2, associated with high risk of metastasis.17,18 Importantly, Class 2 UMs express higher levels of mRNAs related to epithelial lineage (EMP1 and EMP3) and to epithelial cell adhesion and interactions with basement membrane (such as CDH1 and SPARC) that are thought to promote UM cell plasticity, allowing them to become resistant to traditional chemotherapeutic agents.17,19 Among Class 1 UMs, further risk stratification can be performed based on the levels of preferentially expressed antigen in melanoma (PRAME) mRNA, which correlate with increased metastatic risk.20 PRAME also has been proposed as an immunotherapy target.21

Despite these advances in molecular understanding of UM, systemic therapeutic options for metastatic disease remain nonexistent. Thus far, the results from clinical trials evaluating the efficacy of PKC, MEK, c-Kit, MET/VEGF, and CTLA-4 inhibitors in UM patients have failed to improve overall

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
survival. Hence, there is a dire need to identify potential compounds with therapeutic promise.

To this goal, we investigated the efficacy of ICG-001 against UM cells in vitro and in vivo. ICG-001 exerts strong anticancer activity against colorectal cancer, pancreatic cancer, and multiple myeloma. It was identified based on its capacity to disrupt the interaction of β-catenin with the transcriptional coactivator CREB-binding protein (CBP) and, thus, suppress the Wnt/β-catenin-mediated transcriptional program. Our study revealed that ICG-001 induces strong suppression of genes associated with cell cycle, DNA replication, and G1/S transition, stemness, Wnt, and mTORC1 pathways. Furthermore, we observed a strong suppression of genes that are associated with focal adhesion and aggressiveness of Class 2 UM. Application of our transcriptomic signature of ICG-001 to publicly available UM patient datasets showed that ICG-001 induced global transcriptional changes that are associated with decreased metastatic potential and improved clinical outcomes. Lastly, we found that ICG-001 is highly effective in suppressing the migration of UM cells in vitro and is a potent inhibitor of the growth of human UM cells xenografted in mice. Collectively, these results highlight that ICG-001 can be used potentially as a novel therapeutic option for the treatment of UM.

METHODS

Cell Lines and Tissue Culture. The 92.1 UM cell line (carrying a GNAQ Q209L mutation) was established in the lab and was a generous gift of Martine J. Jager. Leiden University Medical Center, Leiden, The Netherlands from a primary UM. The Mel202 cell line (carrying GNAQ Q209L and GNAQR210K mutations) was established from a previously irradiated, locally recurrent primary UM by Bruce R. Ksander (Schepens Eye Research Institute, Boston, MA, USA) and was generously provided by Demetrios Vavvas (Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Harvard Medical School, Boston, MA, USA). The Mel270 cell line (carrying a GNAQ Q209P mutation) was established from a previously irradiated, locally recurrent primary UM by Bruce R. Ksander. A year after the enucleation, the patient suffered liver metastases, from which the OMM1.3 (also known as OMM2.3) and OMM2.5 (also known as OMM1.5) lines were established. These lines were generously provided by Martine J. Jager and Demetrios Vavvas. Genotypes of all cell lines used in this study were authenticated by Sanger sequencing (representative sequence electropherograms have been reported previously and matched what has been reported previously).

All UM lines were confirmed to be BRAF wt. All cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Invitrogen, Carlsbad, CA, USA) with 100 units/mL penicillin, 100 units/mL streptomycin, and 10% fetal bovine serum (FBS; in a 37°C incubator in a humid environment with 5% CO2) and were passaged for <6 months.

MTT Assay. Cell viability after ICG-001 was monitored using MTT assay. ICG-001 was purchased from Selleckchem (Houston, TX, USA). Briefly, cells were plated in 24-well plates and allowed to adhere to the wells for 24 hours, then treated with indicated concentrations of ICG-001 or vehicle control (dimethyl sulfoxide [DMSO], <0.1% vol/vol). After 96 hours, (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; MTT) reagent (Sigma-Aldrich Corp., St. Louis, MO, USA) was added at a final concentration of 50 μg/mL to each well and cells were incubated for 2 more hours. Media were aspirated and equal volume of DMSO/viscouspropanol (1:1 vol/vol) was added to each well to dissolve the precipitated crystals. The optical density was calculated by subtracting absorbance at 630 nM from absorbance at 570 nM and normalized to the respective controls. IC50 was calculated using Prism 7 v7.0b (GraphPad Software, Inc., La Jolla, CA, USA).

Transcriptomic Profiling. Global gene expression profiling was performed to examine the effects of ICG-001 in UM. Cells were treated with 3 μM ICG-001 or DMSO for 24 or 48 hours in six-well tissue culture plates. A detailed methodology is included in the Supplementary Methods.

In Vivo UM Model. All animal experiments were performed in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and the study was approved by the Veterans Affairs Boston Healthcare System Institutional Animal Care and Use Committee (IACUC). Mel270 (GNAQWT) cells were injected subcutaneously (8 × 106 cells/mouse) into the flank of athymic nude mice (n = 10 mice per cohort). Mice were monitored daily and tumor measurements were acquired with digital calipers. Tumor volume was calculated with the formula (width2 × length)/2. Treatment was initiated 3 weeks after subcutaneous cell injection. Mice were treated with intratumoral injection of vehicle or 50 mg/kg ICG-001 (dissolved in 20% polyethylene glycol [PEG], 5% Solutol, 3.75% dextrose, 1% dimethyl sulfoxide [DMSO], sterile PBS) 5 days/week for the duration of the experiment (the first 3 days of treatment were with an induction dose of 100 mg/kg ICG-001). Mice exhibiting any signs of distress or pain, or bearing tumors reaching diameter of 1 cm were euthanized humanely.

Additional methods for flow cytometry, apoptosis measurement, immunoblotting, and wound-healing assay are described in the Supplementary Methods.

RESULTS

ICG-001 Inhibits Proliferation and Induces Apoptosis in UM Cells

ICG-001 treatment resulted in a potent inhibition of cellular proliferation of a panel of UM cell lines in a dose-dependent fashion (Fig. 1A; IC50 range, 0.6–2.7 μM; Supplementary Table S1). Further examination of the effects of ICG-001 on Mel202 and Mel270 cell cycle revealed a decrease in the S and G2/M phase (Fig. 1B, Supplementary Figs. S1A, S1B). An increase in the sub-G1 content also was observed, suggesting the presence of fragmented DNA from apoptotic cells. The presence of apoptotic cells was confirmed by double Annexin V/PI labeling (Supplementary Fig. S2A) and detection of cleaved caspase-3 and PARP (Supplementary Fig. S3A).

ICG-001 Inhibits the Expression of Genes Involved in DNA Replication and Cell Cycle

To further characterize the underlying mechanism behind the inhibition of UM cell proliferation by ICG-001, we next performed global gene expression profiling after treating the Mel202 cells with 3 μM ICG-001. We found 2493 genes to be expressed differentially after 48 hours of treatment with ICG-001 (Supplementary Fig. S2B). Gene set enrichment analysis (GSEA) showed that ICG-001 suppressed a large set of genes involved in key cell cycle processes: DNA replication/synthesis, DNA repair, regulation of the mitotic cell cycle, and cell cycle checkpoints. In addition, we observed a negative enrichment for the gene targets of E2F, a transcription factor family that drives cellular proliferation (Fig. 2).
ICG-001 Inhibits the Expression of Genes Involved in the mTOR Pathway, Wnt Pathway and Stemness

Our GSEA also demonstrated that ICG-001 suppressed the mTORC1 signaling cascade (Fig. 3A). Further evidence of mTOR pathway inhibition was provided by immunoblotting that demonstrated that ICG-001 decreases phospho-p70S6K levels (Supplementary Fig. S3).

Previous studies have suggested that ICG-001 can suppress the Wnt/β-catenin signaling pathway. Thus, we next performed GSEA comparing the ICG-001 transcriptomic footprint against existing gene sets for the Wnt signaling pathway and stemness in MSigDB. These analyses showed that ICG-001 suppressed the Wnt signaling pathway (Fig. 3B). We also compared our ICG-001 signature against a signature that we had generated previously upon silencing WNT5A with siRNA. As shown in Figures 3C and 3D, genes suppressed after ICG-001 were enriched among genes that were suppressed after siWNT5A, while genes induced by ICG-001 were enriched among those upregulated upon silencing WNT5A. ICG-001 did not alter the levels of β-catenin protein in total cell lysates (Supplementary Fig. S3B).

The transcriptomic footprint of ICG-001 also showed a negative enrichment for several gene sets associated with stem cell-like properties ("stemness"). Specifically, we found that gene sets responsible for maintaining human embryonic stem-cell state ("WONG_EMBRYONIC_STEM_CELL_CORE" and "BHATTACHARYA_EMBRYONIC_STEM_CELL"") were suppressed by ICG-001. Furthermore, consistent with data previously published in other models, ICG-001 suppressed
FIGURE 2. ICG-001 suppresses cell cycle gene expression in UM cells. Gene expression profiling was performed with the Illumina HumanHT-12 v4 Expression BeadChip array using RNA harvested from Mel202 cells treated with 3 µM of ICG-001 for 48 hours. Gene set enrichment analyses against MSigDB pathways reveal that ICG-001 potently suppresses cell cycle proliferation, DNA replication, G1/S transition cell cycle, cell cycle checkpoints genes, and transcriptional targets of E2F.
expression of gene sets driven by key stemness-related transcription factors: SOX2, NANOG, OCT4, and MYC (Fig. 3E).

**The ICG-001 Transcriptional Footprint Mimics the Signatures of the Transcriptional SMIs C646 and JQ1**

We next compared the transcriptomic footprint of ICG-001 in UM cells with several previously published ICG-001 signatures derived in various other malignancies. The ICG-001 signature in UM showed strong concordance with previously published ICG-001 signatures from colon cancer (HCT116), pancreatic cancer (PANC1, ASPC1), and hematopoietic stem cells (HSCs; Fig. 4, Supplementary Fig. S4). Interestingly, the ICG-001 signature also mimicked the transcriptomic footprint of C646, a selective SMI of p300 histone acetyltransferase. Moreover, the ICG-001 signature from UM also had high concordance with a signature generated upon silencing EP300 (p300) via siRNA (Fig. 5). We also found that the transcriptomic signature of JQ1, an inhibitor of BET family of bromodomain proteins (BRD) that bind acetylated histones, had high concordance with our ICG-001 transcriptomic footprint. Collectively, these results suggested that ICG-001 can elicit global epigenetic changes in the UM cells that mimic the effects of p300 and BRD inhibition. Interestingly, we observed upregulation of KLF4 protein in ICG-001-treated Mel202 cells (Supplementary Fig. S3F). KLF4 was shown previously to inhibit the interaction of β-catenin with p300.38,39
FIGURE 4. Strong concordance of gene signature of ICG-001 in UM with signatures of ICG-001 and p300 inhibitor in other cancers. Gene set enrichment analysis shows high concordance between the ICG-001 signature from UM and the transcriptomic footprints of ICG-001 (A–D) as well as with the signature of C646 (E–H), a small molecule inhibitor of p300, derived from the HCT116 (colon cancer) and PANC1 (pancreatic cancer) cell lines (GSE64038).
ICG-001 Inhibits Genes Associated With UM Invasiveness and Suppresses UM Cell Invasion In Vitro

A more focused evaluation revealed that ICG-001 was very effective in suppressing genes that are critical for UM aggressiveness. Specifically, we found significant suppression of genes associated with focal adhesion (which, in turn, participates in migration and metastasis) (Fig. 6A). ICG-001 suppressed expression of the SDCBP gene (Fig. 6B), which encodes syntenin-1, a scaffolding-PDZ domain-containing protein with roles in modulating shape, and migration and invasive properties of cancer cells.19–44 and also were downregulated by ICG-001 (Fig. 6B). Interestingly, ICG-001 suppressed SPP1 (Fig. 6B), which encodes the phosphoglycoprotein osteopontin. A recent study showed that osteopontin expression is increased in UM liver metastasis tissue and serum35 compared to primary and/or normal patients. We also found that GAGE cancer/testis antigen family members, that are important players in metastasis, were among the most repressed genes in our ICG-001 signature (Supplementary Fig. S5A).

Following ICG-001 treatment, we also observed suppression of the MAPK/ERK/MEK and the hepatic growth factor (HGF)-mediated signaling pathways (Fig. 6B), which have been shown to promote growth, adhesion, migration, and invasion of UM cells. Further evidence of MAPK/ERK pathway inhibition was provided by immunoblotting, which demonstrated that ICG-001 decreases phospho-ERK1/2 levels (Supplementary Fig. S3). We also examined the levels of total and phospho-YAP1 in whole cell lysates and did not observe any significant changes.

Given our observation that ICG-001 is a potent inhibitor of various genes and signaling pathways that are important for aggressiveness and invasive behavior of UM cells, we next evaluated the effect of ICG-001 using an in vitro wound-healing assay. We found that ICG-001 potently suppressed the ability of UM cells to migrate in vitro (Fig. 6C, Supplementary Fig. S5B).

ICG-001 Inhibits the Expression of Genes Involved in UM Metastasis

Further dissection of the gene expression changes elicited by ICG-001 treatment revealed strong suppression of genes that are associated with metastasis in various UM patient datasets. First, we compared our ICG-001 transcriptomic footprint against a UM patient dataset reported by Onken et al.17–19 They established gene expression-based classification of primary UM: Class 1, associated with low risk of metastasis and Class 2, associated with high risk of metastasis.17,18 Comparison of these respective gene sets against our ICG-001 transcriptomic footprint revealed that ICG-001 suppressed genes that are associated with high metastasis risk, while it induced genes that are associated with low metastasis risk (Figs. 7A, 7B). In subsequent studies, Class 1 UM genes were further subclassified into Class1met and Class1met−, with higher and lower metastatic potential, respectively.20 We also found that numerous genes that are upregulated in Class1met− over Class1met+ UM patients, including PRAME, also were suppressed by ICG-001 treatment (Supplementary Fig. S6). Collectively, our data suggested ICG-001 suppresses genes that are associated with increased metastatic potential in UM.

We also compared our ICG-001 transcriptomic footprint against two additional cutaneous melanoma patient datasets: those of Alonso et al.16 and Winnepennincx et al.17 Genes reported to be upregulated in metastatic tumors in these studies also were enriched among those suppressed by ICG-001 in our transcriptomic signature (Figs. 7C, 7D).

The ICG-001 Transcriptomic Footprint is Associated With Better Overall Survival in UM Patients

In addition, we also performed gene expression profiling after 24 hours of treatment with ICG-001. We found 2413 genes to be expressed differentially in the 24-hour signature, compared to the 2493 genes that were expressed differentially in the 48-hour signature. These two signatures shared a large core set of genes (1510 genes) whose expression was altered concordantly in both. We next applied this core (shared) transcriptomic signature of ICG-001 to the TCGA-UM patient dataset and examined its prognostic significance. We found that the gene expression changes observed after ICG-001 treatment were associated with better overall survival (Fig. 7E).

ICG-001 Suppressed UM Xenograft Growth In Vivo

Finally, we used a Mel270 UM xenograft model to evaluate the anticancer activity of ICG-001 in vivo. For this experiment, Mel270 cells were injected subcutaneously into the flank of athymic nude mice and 50 mg/kg ICG-001 or vehicle control were administered intratumorally 5 days/week. Treatment with ICG-001 substantially reduced growth of UM xenografts compared to the vehicle controls (Fig. 8A) and prolonged animal survival (i.e., delayed the xenografts from reaching diameter of 1 cm, Fig. 8B).

DISCUSSION

Increased understanding and identification of numerous key driver molecules and signaling pathways in UM in the past decade have resulted in the launch of a number of clinical studies with molecularly targeted agents, such as selumetinib, sunitinib, imatinib, vorinostat, and antiangiogenic agents. However, the results of these studies have been disappointing.22–51 Hence, identification of compounds with therapeutic potential in UM is an area of pressing need. We identified ICG-001 as a compound with potent anticancer activity against UM cells in vitro and in vivo.

Global gene expression profiling, along with additional in vitro experiments, allowed us to illuminate several key effects
of ICG-001 in UM. First, ICG-001 resulted in potent suppression of cell cycle genes (such as CDK2, MCM4, MCM7, and CCNB2) and many transcriptional targets of E2F. This suppression of cell cycle genes was accompanied by cell cycle arrest and, eventually, apoptosis. Second, we found that ICG-001 resulted in suppression of the Wnt signaling pathway and inhibited the expression of genes involved in cell “stemness.” The transcriptional footprints of the Sox2, Oct4, Myc, and Nanog transcription factors, which are essential for maintaining the pluripotent embryonic stem-like cell phenotype, were downregulated in our ICG-001 gene expression signature. Third, ICG-001 significantly downregulated a set of epithelial/focal adhesion-related markers (such as E-cadherin) that recently have been shown to be associated with increased metastatic potential in UM.19 Fourth, application of our ICG-001 signature to a UM patient cohort revealed that ICG-001 induced transcriptomic changes associated with better overall survival. Finally, ICG-001 reduced tumor growth and increased overall survival in a murine UM xenograft model.

The major site of UM metastasis is the liver. In recent years, several studies have focused on understanding the role of HGF and its corresponding receptor c-Met in UM pathophysiology. These studies have found that, similar to other cancers, in UM these particular signaling molecules function as mediators of
proliferation, survival, and cell migration. In our study, we found that the transcriptomic footprint of ICG-001 showed downregulation of genes activated by HGF/cMet. Recent studies also have highlighted the GAGE cancer/testis antigen family to be an important player in metastasis; specifically, knockdown of GAGE family members abolished the migratory capacity of cutaneous melanoma cells. Interestingly, we found that GAGE family members were among the most repressed genes in our ICG-001 signature. Correspondingly, we found that ICG-001 completely suppressed the ability of the UM cells to migrate in vitro. The exact role of these GAGE proteins in UM cell invasion and migration remains to be fully elucidated.

Histologic presence of looping vasculogenic mimicry patterns is observed frequently in UM. PKC-driven PI3K/Akt pathway and the Wnt signaling pathway recently have been shown to be important players in vasculogenic mimicry in cancer. Previously, one UM clinical study reported increased presence of the Wnt ligand and the Wnt signaling molecules in primary UM. Our results indicated that ICG-001 exerts inhibitory effects on the Wnt pathway. Strikingly, ICG-001 also was a potent suppressor of many epithelial-related

![Diagram](image_url)

**Figure 7.** ICG-001 suppresses the expression of genes associated with metastasis in vivo and its transcriptomic footprint is associated with increased patient overall survival. (A-D) GSEA of various UM clinical datasets against the transcriptomic footprint of ICG-001 in UM demonstrates that ICG-001 potently suppresses gene expression profiles associated with UM metastasis. (E) The ICG-001 gene expression profile, applied to a UM patient dataset (TCGA) shows a statistically significant association with clinical outcomes. UM patient samples exhibiting low ICG-001 signature (lower 20% of patients) had inferior overall survival.
ICG-001 Elicits Anticancer Activity Against UM

ICG-001 treatment suppressed multiple kinase signaling pathways, including the MAPK/ERK/MEK and the mTOR signaling cascades. Still, their role in the ICG-001-induced cytotoxicity in UM must be clarified further. ICG-001 treatment resulted in inhibition of tumor growth and improved overall survival in a murine xenograft UM model. The xenograft UM model we used is one of the most ubiquitous preclinical models that allows for easy, fast, and accurate measurement of the tumor burden. It incorporates the interaction of the transplanted melanoma cells with the host blood and lymphatic vessels and the study of the drug response in vivo in a rapid and efficient manner. Unfortunately, this particular model rarely develops systemic metastasis and, thus, survival is determined not by metastatic burden but by local tumor growth surpassing the threshold for animal discomfort. The strong antitumor effect of ICG-001 in this murine UM model indicates promising preclinical efficacy that can be translated in the clinic. The formulation of ICG-001 that we used is not adequately soluble in water and, therefore, it was administered intratumorally. A water-soluble version of ICG-001 (PRI-724) that can be administered systemically to patients currently is in clinical trials for solid and hematopoietic malignancies (NCT01606579; NCT01764477).

In summary, we provided, to our knowledge, the first series of evidence that ICG-001 has potent anticancer activity against UM cells in vitro and in vivo. Collectively, our results suggested that ICG-001 is a promising therapeutic agent against UM through inhibition of the cell cycle and several signaling pathways. These data strongly support the rationale for using ICG-001 or its derivatives in future clinical trials in patients with UM.

Acknowledgments

The authors thank Martine J. Jager (Leiden University Medical Center, Leiden, Netherlands), Bruce R. Ksander (Scheepens Eye Research Institute, Boston, USA), and Demetrios Vavvas (Massachusetts Eye and Ear Infirmary and Scheepens Eye Research Institute, Harvard Medical School, Boston, MA, USA) for generously providing UM cell lines and Asha Gowda and David Medina for technical support.

Supported by Merit Review Award I101BX001372 (VP) from the United States Department of Veterans Affairs, National Institutes of Health (NIH, Bethesda, MD, USA; 5T32CA174647-03 [S.K.]), and Cancer Prevention Research Institute of Texas (CPRIT) Grant RP120348 to the Proteomics and Metabolomics Core Facility at BCM. The authors alone are responsible for the content and writing of this paper.

Disclosure: S. Kaochar, None; J. Dong, None; M. Torres, None; K. Rajapakshe, None; F. Nikolos, None; C.M. Davis, None; E.A. Ehli, None; C. Coarfa, None; N. Mitsiades, None; V. Poulaki, None.

References

ICG-001 Elicits Anticancer Activity Against UM


